Highlights

  • BDX shares rose 13.85% to $0.074.
  • Avantect pancreatic and ovarian cancer blood tests became available through Sonic Healthcare centres.
  • A new agreement with Healius provides national access.
  • 91 tests and $88,000 of Revenue were reported following the January launch.

Bcal Diagnostics Ltd (ASX:BDX) shares gained 13.85% to trade at $0.074 on 10 September 2026. BCAL Diagnostics has been accelerating commercialisation of its early-cancer-detection testing portfolio. During 2026, Avantect pancreatic and ovarian cancer blood tests became available through selected Sonic Healthcare centres, with a new Healius agreement providing national access. BCAL reported 91 tests and $88,000 of revenue following the January launch and also submitted an MSAC application concerning pancreatic-cancer screening reimbursement.

Sector Context

Early-cancer-detection diagnostics companies continue to expand pathology-network partnerships to broaden test access, while pursuing reimbursement pathways through bodies such as the Medical Services Advisory Committee.

Risks to Consider

Commercial uptake of new diagnostic tests can take time to scale, and reimbursement outcomes from the MSAC application remain uncertain. Revenue to date, at $88,000, reflects an early stage of commercialisation.

What to Watch Next

Investors will be watching test Volume growth following the Healius agreement and progress on the MSAC application for pancreatic-cancer screening reimbursement.

Conclusion

With national access now expanding through Healius, Bcal Diagnostics' next phase centres on test volume growth and progress toward reimbursement.